Exclusive worldwide rights to develop and commercialize VIA-2291 Based on previous studies, VIA-2291 in more than 1,100 patients, VIA believes that VIA-2291 is safe and well tolerated in doses currently administered in the ongoing clinical trials.. The ACS study is examined from three Phase 2 trials VIA-2291, the firm leading substance cardiovascular disease.
VIA expected top line results from the ACS study soon after the top row CEA report results of the study presented in the third quarter.About VIA 2291VIA-2291 is a selective and reversible inhibitor of 5 – LO, which is probably an important enzyme in the biosynthesis of leukotrienes ). Pharmaceuticals,l trials. Complement to current standard of care therapies, the risk factors, such as statins, antiplatelet and blood pressure to treat drug, VIA-2291 is initially targeted to address the secondary prevention market for patients who a major is a major adverse cardiac event, but eventually benefit might be the broader 15.8 million patients in the U.S.
Under the point of order, legislation would have to increase the entitlement spending, close tax increases or other spending cuts the cost the cost. ,, director of advocacy for AARP that the provision would be dangerous and ultimately hold Medicare and other mandatory federal programs hostage to rising health care costs. added, added, These unbalanced limitations would apply to any other expenditure programs, nor would it apply to the revenue side of the ledger (Cohn, CongressDaily.. Continue reading “The ACS study is examined from three Phase 2 trials VIA-2291.”